CannTrust Holdings Inc. (NYSE:CTST) produced a 20.58% rally since recording the worst price of $2.43. Thanks to the latest 2.45% increase, it now trades at $2.93. Throughout the trading on 7/18/2019, the share price floated between $2.68 and $3.18. This company shares are -100% up from its target price of $0 and the current market capitalization stands at $0. The recent change has given its price a -41.97% deficit over SMA 50 and -75.53% deficit over its 52-week high. The stock witnessed -40.57% declines, -59.7% declines and -53.04% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CTST’s volatility during a week at 17.95% and during a month it has been found around 9.16%.
What Does CannTrust Holdings Inc. (CTST) Do?
The company describes itself in regulatory filings as, “CannTrust Holdings, Inc. engages in the production and distribution of medical cannabis. It focuses on developing nanotechnology to create new products in the medical, recreational, beauty, wellness, and pet markets. The company was founded by Norman Paul and Eric Paul on March 16, 2015 and is headquartered in Vaughan, Canada.” [Text can be found here: https://www.marketwatch.com/investing/stock/CTST/profile under company description.]CannTrust Holdings Inc. 13F Filings
At the end of March reporting period, 68 institutional holders increased their position in CannTrust Holdings Inc. (NYSE:CTST) by some 7,388,275 shares, decreased positions by and 3 held positions by 785,241. That puts total institutional holdings at 8,173,516 shares, according to SEC filings. The stock grabbed 64 new institutional investments totaling 7,334,701 shares while institutional investors sold out their entire positions totaling shares.CannTrust Holdings Inc. (CTST) Analyst Guide
Several analysts have released their opinion on CannTrust Holdings Inc. (NYSE:CTST), with 2 analysts believing it is a strong buy. Whereas 6 of them predict the stock is a hold. Also, there are 0 buy, 1 sell and 1 strong sell ratings, collectively assigning a 2.9 average brokerage recommendation [T1].